Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.79 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.79 |
| ▸ | RELA | Q04206 | 3/20 | 0.79 |
| ▸ | GAA | P10253 | 2/20 | 0.79 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.68 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325903 | 0.97 | ALDH1A1 (0.94) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2617338 | 0.88 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2103248 | 0.87 | ALDH1A1 (0.79) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL13133695 | 0.87 | ALDH1A1 (0.76) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4728827 | 0.85 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL5420774 | 0.85 | NPC1 (0.77) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL5866078 | 0.85 | ALDH1A1 (0.74) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL28851904 | 0.85 | RAB9A (1.00) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL5409082 | 0.85 | RAB9A (0.77) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL972723 | 0.85 | NPC1 (0.77) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812530-A | Method for preparing imidazole pyridine compound by catalyzing lignin and model compound by Pd/C bi-component system | 中国科学院大连化学物理研究所 | 2024-10-22 | — | — | CN | claimed |
| CN-118812530-A | Method for preparing imidazole pyridine compound by catalyzing lignin and model compound by Pd/C bi-component system | 中国科学院大连化学物理研究所 | 2024-10-22 | — | — | CN | disclosed |
| CN-117946101-A | Aryl methyl sulfone compound and synthesis method thereof | 中国人民解放军军事科学院防化研究院 | 2024-04-30 | — | — | CN | disclosed |
| EP-1582516-B1 | Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same | IDEMITSU KOSAN CO (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-7867629-B2 | Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7867629-B2 | Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-4242513-A | CHROMOGENS; PRESSURE AND HEAT SENSITIVE MARKING | APPLETON PAPERS INC. (US) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | ALDH1A1 1864/4885NPC1 4504/4885RAB9A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.